Abstract: Objective: To assess the effects of antiplatelet agents using thrombelastography in patients with percutaneous coronary intervention (PCI). Method: A total of 168 patients with coronary heart disease in our hospital between May 2011 and April 2015 were enrolled in this study. Among them, 56 patients who treated with PCI and took aspirin and clopidogrel were chosen as combination group, 56 patients who did not receive PCI and took aspirin only as aspirin group and 56 cases who did not receive PCI and took clopidogrel only as clopidogrel group. The platelet inhibition rates induced by arachidonic acid (AA) pathway and adenosine diphosphate (ADP) pathway were detected by thrombelastography, and the related factors influencing the sensitivity of antiplatelet drugs were analyzed. Result: ①The platelet inhibition rates induced by AA pathway was no significant difference (P>0.05) between combination group and aspirin group, and the rates induced by ADP pathway was no significant difference (P>0.05) between combination group and clopidogrel group. ②The sensitivity of aspirin was associated with smoking, obesity, hyperlipidemia and diabetes (P<0.05), and the sensitivity of clopidogrel was related to gender, smoking, obesity and diabetes (P<0.05). Conclusion: The patients who were insensitive to antiplatelet agents could be found in a timely manner by thrombelastography, thus to formulate individualized antiplatelet therapies.